Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05165745 · ClinicalTrials.gov registry record · NA

Stick2PrEP Cisgender Women and Trans Individuals

A NA study of HIV Prevention and Pre-exposure Prophylaxis, sponsored by Columbia University.

Recruiting
Registry status
NA
Development phase
175
Enrollment target
1
Study location

NCT05165745: Recruiting NA study of HIV Prevention and Pre-exposure Prophylaxis, sponsored by Columbia University.

NCT05165745 is a NA study of HIV Prevention and Pre-exposure Prophylaxis that is actively recruiting participants, run by Columbia University. The registered enrollment target is 175 participants, below the 376-participant average among 32 other HIV Prevention trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05165745, a NA study of HIV Prevention and Pre-exposure Prophylaxis, is actively recruiting participants, sponsored by Columbia University.

RECRUITING
Registry status
NA
Development phase
175 participants
Enrollment target
1
Study location

Study Summary

Taking a daily anti-HIV pill can protect people from HIV infection. This is called preexposure prophylaxis \[PrEP\]. Many cisgender women and trans individuals do not know this medication is available; others struggle to take the pill every day. It is important to understand attitudes and preferences about HIV prevention options, especially as new options become available. This study plans to evaluate preferences over time among cisgender women and trans individuals who are taking medication to prevent HIV, and among cisgender women and trans individuals who are not taking medication but are at risk of HIV. The investigators enroll up to 175 participants who visit the HIV prevention clinic, and the investigators will ask participants to complete questionnaires at regular follow up visits and between visits. This study may help the investigators understand how best to prevent HIV among people at risk.

Primary Outcome

Description of CWTI's preferences for different PrEP modalities and the relationship between preference and PrEP initiation/persistence in care. Preferences are evaluated using questionnaires developed by the study team; questions include ranked choice and Likert score responses. Persistence in care is measured by using the electronic medical record to track sexual health care visits over study period.

Interventions

  • BEHAVIORAL Individualized Feedback

Study Locations (1)

New York

  • Columbia University Medical Center - New York

Trial Details

FieldValue
Enrollment Target 175 participants
Start Date 2021-10-25
Est. Completion 2026-10-25
Phase NA
Columbia University

958 total trials

What NCT05165745 shows while recruiting

NCT05165745 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 32 other HIV Prevention trials with a reported enrollment target (53% lower).

The record links to 2 conditions, with HIV Prevention appearing as the primary indexed condition, and to 1 intervention - of which Individualized Feedback is the first listed.

NCT05165745 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05165745 about?

NCT05165745 is a clinical study titled "Stick2PrEP Cisgender Women and Trans Individuals". Taking a daily anti-HIV pill can protect people from HIV infection. This is called preexposure prophylaxis \[PrEP\]. Many cisgender women and trans individuals do not know this medication is available; others struggle to take the pill every day. It is important to understand attitudes and preference...

What is the current status of trial NCT05165745?

This trial is currently recruiting. It is a NA study. The enrollment target is 175 participants. The study started on 2021-10-25. Estimated completion is 2026-10-25.

What conditions does trial NCT05165745 study?

This clinical trial studies the following conditions: HIV Prevention, Pre-exposure Prophylaxis.

What interventions are being tested in trial NCT05165745?

The interventions under investigation include: Individualized Feedback (BEHAVIORAL).

Who is sponsoring clinical trial NCT05165745?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05165745 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV Prevention

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05165745's enrollment target sits among peer trials

175 14th of 32 higher than 19 of 32 other HIV Prevention trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV Prevention trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04722341 · 175 participants · NA

    Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators

  • NCT05094037 · 175 participants · NA

    Orthotic Treatment of Diabetic Foot Ulcers

  • NCT05312255 · 175 participants · NA

    Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

  • NCT05335876 · 175 participants · Phase 3

    Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05165745, the US trial registry maintained by the National Library of Medicine. NCT05165745 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.